Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Repurposing Leptin (Part 2): It Really Is A One-In-A-Million Drug

This article was originally published in RPM Report

Executive Summary

Two decades after the “obesity gene” was the hottest story in biotech, a product from that research is finally going to reach the market. But it is for a disease that occurs in about .0001% of the US population.

Advertisement

Related Content

Orphans Should Live Alone
One In A Million: Aegerion Looks To Raise The Price Of Myalept
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
FDA Panel Backs Efficacy Of BioMarin’s Rare Disease Drug Vimizim
Repurposing Leptin: How a “Fat Drug” Became a Model for a Leaner Industry
Aegerion Juxtapid Launch Targets Population Far Broader Than FDA Projection

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079673

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel